RAC 2.92% $1.94 race oncology ltd

Ann: Expanded Heart Protection Discovery for Zantrene, page-180

  1. 8,405 Posts.
    lightbulb Created with Sketch. 1383
    Welcome to posting @EllaEm
    Please post often.

    The debate in this case is about a (bisantrene + drug X) coformulation versus drug X alone
    where
    old SoC = drug X which has recently become generic
    new SoC = (bisantrene + drug X) coformulation.

    So it isn't about different brands of the same drug.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.